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Abstract
Objective:  We  aimed  to  describe  sociodemographic,  comorbidities,  co-medication  and  risk  of
thromboembolic  events  and  bleeding  in  patients  with  NVAF  initiating  oral  anticoagulants  (OAC)
for stroke  prevention,  and  to  estimate  adherence  and  persistence  to  OAC.
Setting:  Primary  Health  Care  (PHC)  in  the  Catalan  Health  Institute  (ICS),  Catalunya,  Spain.
Participants:  All  NVAF  adult  patients  initiating  OAC  for  stroke  prevention  in  August
2013--December  2015.
Methods:  Population-based  cohort  study.  Persistence  was  measured  in  patients  initiating  OAC
in August  2013--December  2014.
Data  source:  SIDIAP,  which  captures  electronic  health  records  from  PHC  in  the  (ICS),  covering
approximately  5.8  million  people.
Results:  51,690  NVAF  patients  initiated  OAC;  47,197  (91.3%)  were  naive  to  OAC  and  32,404
(62.7%) initiated  acenocoumarol.  Mean  age  was  72.8  years  (SD  12.3)  and  49.4%  were  women.
tors  were  taken  by  9105  (17.6%)  of  the  patients.  Persistence  and
 up  to  the  end  of  follow-up.  For  22,075  patients,  persistence  was
 patients  [n  =  258  (61.7%)]  than  among  the  naive  [n  =  11,502  (53.1%)].Platelet-aggregation  inhibi
adherence were  estimated
higher among  the  non-naive∗ Corresponding author.
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Adherence  was  estimated  for  patients  initiating  DOAC  and  it  was  similar  in  naive  and  non-naive
patients.  Among  the  naive  to  DOAC  treatment,  those  starting  rivaroxaban  showed  a  highest
proportion  [(n  =  360  (80.1%)]  of  good  adherence  at  implementation  (MPR  >  80%)  while  patients
starting dabigatran  were  less  adherent  [n  =  203  (47.8%)].
Conclusions:  Acenocoumarol  was  the  most  frequently  prescribed  OAC  as  first  therapy  in  NVAF
patients.  Non-naive  to  DOAC  showed  better  persistence  than  naive.  Rivaroxaban  showed  higher
proportion  of  adherent  patients  during  the  implementation  phase  than  apixaban  and  dabigatran
the lowest.
©  2020  The  Authors.  Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Uso  y  adherencia  a  los  anticoagulantes  orales  en  Atención  Primaria  en  Cataluña,
España:  estudio  de  cohortes  con  datos  procedentes  de  registros  electrónicos  de  salud
Resumen
Objetivo:  Describir  datos  sociodemográficos,  comorbilidades,  comedicaciones  y  riesgo  de  even-
tos tromboembólicos  y  hemorrágicos  de  los  pacientes  con  fibrilación  auricular  no  valvular  (FANV)
que inician  tratamiento  anticoagulante  por  vía  oral  (TAO)  para  prevención  del  ictus.  Estimar
adherencia  y  persistencia  al  TAO.
Emplazamiento:  Atención  primaria  (AP)  del  Instituto  Catalán  de  Salud  (ICS),  Cataluña,  España.
Participantes:  Adultos  con  FANV  que  inician  TAO  para  prevención  de  ictus  entre  agosto  del  2013
y diciembre  del  2015.
Métodos:  Estudio  de  cohortes  de  base  poblacional.  Adherencia  y  persistencia  se  midieron  en
pacientes  que  iniciaban  TAO  entre  agosto  del  2013  y  diciembre  del  2014.
Fuente de  datos:  SIDIAP,  base  de  datos  procedentes  de  registros  electrónicos  de  AP  del  ICS,  que
cubre aproximadamente  una  población  de  5,8  millones  de  personas.
Resultados:  Cincuenta  y  un  mil  seiscientos  noventa  pacientes  con  FANV  iniciaron  TAO,
47.197 (91,3%)  eran  naïve  al  TAO  y  32.404  (62,7%)  iniciaron  acenocumarol.  Su  edad  media  era
72,8 años  (DE  12,3)  y  el  49,4%  eran  mujeres;  90105  (17,6%)  recibían  tratamiento  antiagregante
plaquetario.  Persistencia  y  adherencia  se  estimaron  hasta  el  final  del  seguimiento.  La  persis-
tencia a  anticoagulantes  orales  directos  (ACOD)  fue  mayor  en  no  naïve  que  en  naïve  (61,7%  vs.
53,1%). La  adherencia  a  ACOD  fue  similar  en  los  2  grupos.  Entre  los  naïve,  los  pacientes  que
iniciaban  rivaroxabán  (80,1%)  mostraron  mayor  adherencia  en  la  implementación  (MPR  >  80%),
mientras que  los  que  iniciaban  dabigatrán  fueron  menos  adherentes  (47,8%).
Conclusiones:  Acenocumarol  fue  el  anticoagulante  más  prescrito.  Los  pacientes  no  naïve
mostraron  mejor  persistencia  al  tratamiento  que  los  naïve.  Rivaroxabán  mostró  mayores  tasas
de adherencia  que  apixabán  y  dabigatrán,  las  menores.
© 2020  Los  Autores.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un  art́ıculo  Open  Access  bajo
la licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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irect  oral  anticoagulants  (DOAC)  have  been  authorised  by
he  European  Medicines  Agency  for  stroke  prevention  and
ystemic  embolism  in  adult  patients  with  non-valvular  atrial
brillation  (NVAF)  during  the  last  years  (in  Spain  the  launch
ate  was  2011  for  dabigatran,  2012  for  rivaroxaban,  2013  for
pixaban  and  2016  for  edoxaban).  Their  efficacy  and  safety
ave  been  demonstrated  in  their  respective  pivotal  clinical
rials.1--4
The  level  of  utilisation  of  the  different  DOAC  in  stroke
revention  in  NVAF  has  shown  to  be  different  among
ountries,  and  several  cohort  studies  have  shown  dissimi-
ar  results  on  effectiveness  and  safety  of  these  drugs.5--12
dequate  levels  of  adherence  and  persistence  to  anticoag-
lant  treatment  have  shown  to  decrease  the  occurrence  of
v
t
A
(
mbolic  events,13--16 so  other  studies  have  assessed  adher-
nce  and  persistence  to  oral  anticoagulants  (OAC),  also
howing  different  results  among  them.17--23 Adherence  has
een  defined  as  the  extent  to  which  the  patient  conforms  to
he  medication  use  recommendations  specified  by  the  pre-
criber  (frequency  of  administration,  dosage,  etc.),  and  it
s  divided  in  three  phases:  initiation,  implementation  and
ersistence.24 Initiation  can  be  estimated  by  the  prescrip-
ions  actually  dispensed,  implementation  can  be  measured
y  medication  possession  ratio  (MPR),  and  persistence  is
efined  as  the  continuation  of  the  treatment  over  time.25
Despite  the  introduction  of  DOAC  for  NVAF  management,
itamin  K  antagonists  (VKA)  are  still  the  first  therapeu-
ic  option  for  stroke  prevention  in  Spain,  according  to  the
gencia  Española  de  Medicamentos  y  Productos  Sanitarios
AEMPS).26
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Use  and  adherence  of  oral  anticoagulants  in  Primary  Health  
We  have  recently  described  apixaban  patients’  charac-
teristics  according  to  demographics,  comorbidity,  risk  of
thromboembolic  events  and  comedications  in  a  paper.27
The  aim  of  the  present  work  was  to  describe  the  char-
acteristics  for  all  patients  initiating  any  oral  anticoagulant
drug  (DOAC  and  VKA)  for  stroke  prevention  in  NVAF  and  to
estimate  adherence  during  the  implementation  phase  and
persistence  to  DOAC  treatment.
Material and methods
This  is  an  observational  population-based  cohort  study  of
adult  patients  receiving  DOAC  and  VKA  for  stroke  prevention
in  NVAF,  identified  in  the  primary  healthcare  (PHC)  database
SIDIAP  (Information  System  for  Research  in  Primary  Care)28
in  Catalonia,  Spain.  The  study  cohort  included  all  individ-
uals  diagnosed  with  NVAF  who  had  a  new  prescription  for
apixaban,  dabigatran,  rivaroxaban  or  VKA  (acenocoumarol
or  warfarin)  from  August  2013  until  December  2015.  We
excluded  from  the  study  those  patients  with  a  regis-
tered  diagnosis  of  valvular  heart  disease,  including  patients
with  mitral  prosthetic  valves.  All  patients  enrolled  were
subdivided  in  four  groups  according  to  the  treatment  initi-
ated:  apixaban,  dabigatran,  rivaroxaban  and  VKA.  Patients
were  considered  naive  if  they  did  not  have  prior  prescrip-
tion  of  any  OAC  during  12  months  before  index  date,  or
non-naive  if  they  had  been  previously  treated  during  the
previous  12  months  with  a  different  OAC  from  the  OAC
that  caused  the  entrance  to  the  study  cohort.  Patients
were  followed-up  until  the  discontinuation  of  anticoagulant
treatment.
The  data  source  was  SIDIAP,28 which  currently  collects
anonymized  information  from  279  primary  health  care  cen-
tres  managed  by  the  Catalan  health  institute  (ICS),  which
covers  more  than  5.8  million  patients  (approximately  80%  of
the  Catalonia  population,  or  more  than  10%  of  the  Spanish
population).  The  information  in  SIDIAP  is  generated  from  dif-
ferent  data  sources:  (1)  ECAPTM (electronic  health  records
in  PHC);  which  includes  information  since  2006  on  sociode-
mographic  characteristics,  health  conditions  registered  as
ICD-10  codes,29 General  Practitioners’  prescriptions,  clini-
cal  parameters  and  toxic  habits.  (2)  Laboratory  data.  (3)
Pharmacy  invoice  data  available  since  2005:  information  on
all  pharmaceutical  products  dispensed  by  community  phar-
macies  with  ICS  prescriptions,  by  ATC  codes.30
We  first  described  demographics,  comorbidity,  risk  of
thromboembolic  events  and  comedications  of  all  patients
with  a  new  prescription  of  OAC,  and  secondly,  we  described
medication  adherence  during  implementation  and  persis-
tence  to  anticoagulant  treatment  for  those  patients  whose
dispensing  data  were  available  and  had  at  least  one  year
of  follow-up  in  SIDIAP  database,  during  the  period  between
August  2013  and  December  2014  in  order  to  analyse  data  of
at  least  one  year  after  initiation.
To  calculate  adherence  during  implementation  and
persistence  phases  we  only  took  into  account  those  patients
who  were  adherent  during  initiation,  meaning  those  who
had  OAC  prescribed  and  dispensed.  Persistence  was  defined
as  no  discontinuation  of  treatment.  Discontinuation  rates  of
OAC  were  defined  by  lack  of  subsequent  dispensing  of  the
index  drugs  within  2  months  after  last  supply  day  of  the  last
E
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ispensing  and  were  analysed  by  calculating  the  cumulative
ercentage  of  discontinuation  (treatment  withdrawal  or
witch)  rate.
Therapeutic  adherence  during  the  implementation  phase
as  estimated  by  MPR,  which  is  the  ratio  between  the  days
f  treatment  covered  by  the  medication  dispensed  and  the
otal  number  of  days  between  the  index  date  and  the  last
ispensing,  and  it  was  measured  in  persistent  patients  (those
ith  at  least  one  year  of  no  discontinuation).  Values  of  MPR
bove  80%  were  considered  as  good  adherence  during  imple-
entation.  The  package  size  has  been  used  to  estimate  days
f  supply  for  DOACs  (rivaroxaban  once  daily,  dabigatran  and
pixaban  twice  daily)  as  the  WHO  method  estimation  using
efined  daily  dose  does  not  separate  between  standard  and
ow  dose.30 Adherence  of  VKA  treatment  cannot  be  properly
stimated  with  the  same  method,  as  doses  are  not  the  same
or  every  day  of  the  week,  they  change  after  INR  alterations
nd,  moreover,  warfarin  and  acenocoumarol  pharmaceuti-
al  products  in  Spain  are  available  at  different  doses  and
ontain  different  numbers  of  tablets.  Thus,  adherence  data
n  this  paper  are  only  described  for  DOAC.
tatistical  analysis
ociodemographic  characteristics  for  the  four  groups  at
he  start  date  are  provided:  (1)  for  all  variables,  num-
er  and  percentage  of  missing  data;  (2)  for  categorical
ariables  (sex,  toxic  habits  and  MEDEA  index31),  num-
er  and  percentage  for  each  category;  (3)  for  continuous
ariables  (age,  body  mass  index),  mean  and  standard  devi-
tion  (SD).  We  report  the  total  number  of  patients  with
t  least  one  disease  and  the  number  and  percentage  of
atients  with  each  specific  condition  for  all  groups  (apix-
ban,  dabigatran,  rivaroxaban  and  VKA).  Concurrent  use  of
edications  at  the  start  date  was  quantified  by  the  num-
er  and  percentage  of  users.  Risk  of  stroke  and  major
aemorrhage  event  were  assessed  at  the  start  date  with
HA2DS2VASc32 and  HAS-BLED.33 For  each  score,  number  and
ercentage  of  each  category  for  the  five  drugs  groups  are
escribed.
Monthly  discontinuation  rates  for  all  anticoagulant  during
he  first  year  of  treatment  were  also  calculated  in  order  to
stimate  the  persistence.  We  conducted  survival  analyses
f  the  time  from  the  index  date  to  the  discontinuation  date
sing  survival  curves  drawn  using  the  Kaplan--Meier  method.
ensoring  was  considered  at  end  of  follow-up,  death  or  date
f  treatment  discontinuation.  For  each  DOAC  group,  number
nd  percentage  of  users  with  good  adherence  and  summary
tatistics  for  MPR  were  estimated.
Analysis  was  conducted  using  SAS  software,  version  9.4
SAS  Institute).  Detailed  methodology  for  summary  and
tatistical  analyses  of  data  collected  in  this  study  are  doc-
mented  in  the  Statistical  Analysis  Plan,  which  is  dated,
led  and  maintained  by  the  sponsor  and  can  be  accessed
t  request  to  the  corresponding  author.thics  approval
he  study  protocol  was  approved  by  the  Ethics  Committee
f  the  ‘IDIAPJGol’  and  classified  by  the  AEMPS.
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USERS
100, 320 NVAF
patients with a
prescription of
anticoagulants in
Aug 2013-Dec 2015
51,690 NVAF patients
with
a new
prescription of
anticoagulants in Aug
2013-Dec 2015
Apixaban 1,082
(4.9%)
Dabigatran 1,255
(5.7%)
Rivaroxaban 1,459
(6.6%)
VKA 18,279(82.9)
Apixaban 6,135
(11.8%)
Dabigatran 3,808
(7.4%)
Rivaroxaban 6,694
(13%)
VKA 35,053 (67.8%)
Apixaban 2,549
(6.2%)
Dabigatran 2,245
(5.5%)
Rivaroxaban 3,361
(8.2%)
VKA 32,991 (80.1%)
22,075 NVAF patients
initiating
anticoagulant
treatment in Aug
2013-Dec 2014
41,146 NVAF patients
with dispensing
register of
anticoagulants in
SIDIAP in Aug 2013-
Dec 2015
Apixaban 6,169
(6.1%)
Dabigatran 5,485
(5.5%)
Rivaroxaban 7,703
(7.7%)
VKA 80,963 (80.7%)
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Figure  1  Flowchart  of  patients  included  in  the  study.  NV
esults
e  analysed  51,690  NVAF  patients  with  a  new  OAC  pres-
ription  during  the  study  period;  47,197  (91.3%)  were  OAC
aive  patients  and  4493  (8.7%)  were  non-naive,  and  out  of
he  overall  number  of  patients,  16,637  (32.2%)  received  a
OAC  prescription  and  35,053  (67.8%),  VKA  (Fig.  1,  Table  1).
emographics,  risk  of  stroke  and  haemorrhage,  comorbidi-
ies  and  comedications  are  described  in  Table  1.  Patients
nitiating  anticoagulants  had  a  mean  age  of  72.8  years  (SD
2.3),  49.4%%  of  them  were  women  and  83.9%  of  patients
ad  a  CHA2DS2VASc  score  ≥2.  The  youngest  patients  were
hose  initiating  warfarin  (70.5  years)  and  the  oldest,  those
ith  acenocoumarol  (73.5).  There  was  a  higher  proportion  of
atients  prescribed  with  apixaban  with  a  CHA2DS2VASc  score
2  than  for  the  rest  of  the  drugs  (86.1%)  and  the  highest
aemorrhagic  risk  was  for  acenocoumarol-treated  patients
40.6%  with  HAS-BLED  ≥3  as  compared  to  23.1--35.0%
atients  with  HAS-BLED  ≥3  in  patients  receiving  other  OAC).
he  most  frequent  comorbidities  were  hypertension  (68%),
iabetes  (31.7%)  and  cancer  (25.6%),  and  the  most  fre-
uent  comedications  were  proton  pump  inhibitors  (60.4%),
gents  acting  on  the  renin--angiotensin  system  (55.9%)  and
tatins  (42.4%).  Dispensing  data  were  available  for  41,146
atients  (79.6%)  of  those  patients;  8155  (19.9%)  patients
nitiated  DOAC  treatment  and  32,991  (80.1%)  initiated
KA  (Fig.  1).
Adherence  at  implementation  and  persistence  were
ssessed  through  dispensing  data  for  patients  who  initiated
nticoagulant  treatment  with  OAC  between  August  2013
nd  December  2014  (n  =  22,075),  being  only  1.9%  of  them
n  =  418)  non-naive  patients.  Of  the  22,075  patients,  3796
17.2%)  received  DOAC;  3425  (n  =  15.8%)  of  them  were  naive
nd  371  (88.7%)  were  anticoagulant-experienced  patients
Table  2).
During  the  first  month  of  treatment,  all  DOAC-naive
atients  presented  high  discontinuation  rates,  being  the
iscontinuation  rates  higher  for  apixaban  (33.1%)  than
p
V
i
p
on-valvular  atrial  fibrillation,  VKA:  vitamin  K  antagonists.
or  rivaroxaban  (30.6%)  and  for  dabigatran  (24.2%).
iscontinuation  rates  in  naive  patients  after  one  year  of
reatment  were  similar  between  the  three  DOAC,  with
pproximately  60%  of  patients  stopping  treatment.  In  all
he  naive  patients  the  persistence  at  one  year  was  less  than
0%  except  for  the  acenocoumarol  naive  patients  in  whom  it
as  of  56.8%.  Persistence  was  higher  in  non-naive  patients
ith  an  observed  persistence  of  more  than  50%  at  one  year,
eing  higher  for  warfarin  non-naive  patients  (77.1%)  than
or  DOAC,  where  the  maximum  persistence  was  observed  for
pixaban  patients  (66.1%)  and  the  minimum  for  the  dabiga-
ran  (48.5%)  patients.
For  the  DOAC  naive  patients  with  at  least  one  year  of
ollow-up  (n  =  1299,  37.9%,  Table  3),  the  highest  adherence
t  implementation  was  for  rivaroxaban  (80.1%),  followed
y  apixaban  (61.3%)  and  dabigatran  (47.8%).  For  DOAC
on-naive,  225  (60.6%)  patients  did  not  discontinue  DOAC
reatment  during  the  first  year  and  among  them,  the  largest
roportion  of  patients  with  good  adherence  was  for  rivaroxa-
an  (81.7%)  and  the  lowest  for  dabigatran  (34.0%).  Although
he  measure  of  persistence  for  VKA  should  be  different  to  the
easure  for  DOAC,  in  Fig.  2  we  show  data  for  both  groups  of
nticoagulants  in  order  to  compare  them.  This  figure  shows
aplan--Meier  curves  for  treatment  discontinuation  of  DOAC
nd  VKA  in  naive  patients;  there  were  high  DOAC  discon-
inuation  rates  at  treatment  start  and,  over  time  apixaban
howed  lower  discontinuation  rates.
iscussion
e  included  51,690  new  users  of  OAC  in  this  population-
ased  cohort  study,  41,146  of  them  had  dispensing  data
vailable  in  SIDIAP  (79.6%).  Approximately  80%  of  the
atients  initiated  VKA  rather  than  DOAC,  pointing  out  that
KA  are  still  the  first  therapeutic  option  for  anticoagulation
n  NVAF  in  our  setting,  as  recommended  by  AEMPS.26 Most
atients  (83.9%)  had  CHA2DS2VASc  score  ≥2,  which  is  the
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Table  1  Baseline  characteristics  of  patients  with  new  prescriptions  of  anticoagulants.
N, % Total
(n = 51,690)
Apixaban
(n = 6135)
Dabigatran
(n = 3808)
Rivaroxaban
(n = 6694)
Acenocoumarol
(n = 32,404)
Warfarin
(n = 2649)
Naive patients 47,197 (91.3%) 4712 (76.8%) 2855 (75.0%) 5132 (76.7%) 32,212 (99.4%) 2286 (86.3%)
Non-naive patients 4493 (8.7%) 1423 (23.2%) 953 (25.0%) 1562 (23.3%) 192 (0.6%) 363 (13.7%)
Female  25,559 (49.4%) 3412 (55.6%) 1878 (49.3%) 3460 (51.7%) 15,625 (48.2%) 1184 (44.7%)
Mean  age, years (SD) 72.8 (12.3) 73.2 (11.0) 71.6 (12.0) 71.0 (12.9) 73.5 (12.3) 70.5 (13.5)
≥80  years-old 17,200 (33.3%) 1879 (30.6%) 1065 (28.0%) 1809 (27.0%) 11,737 (36.2%) 710 (26.8%)
Smoking  habit 11,701 (22.6%) 1313 (21.4%) 826 (21.7%) 1483 (22.2%) 7302 (22.5%) 777 (29.3%)
Glomerular filtration rate (mL/min/1.73 m2)
Missing GFR 9788 (18.9%) 1249 (20.4%) 839 (22.0%) 1636 (24.4%) 5561 (17.2%) 503 (19.0%)
GFR  ≥ 60 30,687 (59.4%) 3605 (58.8%) 2363 (62.1%) 3908 (58.4%) 19,248 (59.4%) 1563 (59.0%)
GFR  30--45 10,248 (19.8%) 1198 (19.5%) 577 (15.1%) 1088 (16.3%) 6867 (21.1%) 518 (19.6%)
GFR  < 30 967 (1.9%) 83 (1.4%) 29 (0.8%) 62 (0.9%) 728 (2.2%) 65 (2.5%)
BMI  groups (kg/m2)
Missing 12,408 (24.0%) 1685 (27.5%) 1138 (29.9%) 2057 (30.7%) 6932 (21.4%) 596 (22.5%)
18.5--25  (normal) 6701 (13.0%) 676 (11.0%) 416 (10.9%) 735 (11.0%) 4501 (13.9%) 373 (14.1%)
<18.5  (underweight) 201 (0.4%) 18 (0.3%) 18 (0.5%) 16 (0.2%) 141 (0.4%) 8 (0.3%)
25--30  (overweight) 15,507 (30.0%) 1722 (28.1%) 1041 (27.3%) 1771 (26.5%) 10,142 (31.3%) 831 (31.4%)
>30  (obese) 16,873 (32.6%) 2034 (33.2%) 1195 (31.4%) 2115 (31.6%) 10,688 (33.0%) 841 (31.7%)
CHA2DS2VASc
0 or 1 (woman) 4902 (9.5%) 480 (7.8%) 476 (12.5%) 887 (13.3%) 2738 (8.4%) 321 (12.1%)
1  3398 (6.6%) 375 (6.1%) 280 (7.4%) 500 (7.5%) 2040 (6.3%) 203 (7.7%)
≥2 43,390 (83.9%) 5280 (86.1%) 3052 (80.1%) 5307 (79.2%) 27,626 (85.3%) 2125 (80.2%)
HAS-BLED
0  4166 (8.1%) 540 (8.8%) 509 (13.4%) 903 (13.5%) 1918 (5.9%) 296 (11.2%)
1--2  29,391 (56.9%) 3927 (64.0%) 2405 (63.2%) 4243 (63.4%) 17,322 (53.5%) 1494 (56.4%)
≥3  18,133 (35.0%) 1668 (27.2%) 894 (23.4%) 1548 (23.1%) 13,164 (40.6%) 859 (32.4%)
Comorbidities
Heart  failure 6133 (11.9%) 866 (14.1%) 439 (11.5%) 783 (11.7%) 3656 (11.3%) 389 (14.7%)
Peripheral artery disease 2764 (5.3%) 323 (5.3%) 154 (4.0%) 294 (4.4%) 1801 (5.6%) 192 (7.2%)
Ischaemic heart disease 7406 (14.3%) 802 (13.1%) 472 (12.4%) 856 (12.8%) 4795 (14.8%) 481 (18.2%)
Acute  myocardial infarction 2460 (4.8%) 246 (4.0%) 130 (3.4%) 263 (3.9%) 1638 (5.1%) 183 (6.9%)
Hypertension 35,144 (68.0%) 4295 (70.0%) 2428 (63.8%) 4364 (65.2%) 22,305 (68.8%) 1752 (66.1%)
Diabetes  mellitus 16,403 (31.7%) 1986 (32.4%) 1146 (30.1%) 1981 (29.6%) 10,425 (32.2%) 865 (32.7%)
Cerebrovascular disease 6248 (12.1%) 891 (14.5%) 523 (13.7%) 731 (10.9%) 3725 (11.5%) 378 (14.3%)
Cancer  13,211 (25.6%) 1606 (26.2%) 940 (24.7%) 1698 (25.4%) 8249 (25.5%) 718 (27.1%)
Comedications
Proton  pump inhibitors 31,200 (60.4%) 4308 (70.2%) 2346 (61.6%) 4357 (65.1%) 18,489 (57.1%) 1700 (64.2%)
Drugs  used in diabetes 11,684 (22.6%) 1404 (22.9%) 805 (21.1%) 1348 (20.1%) 7494 (23.1%) 633 (23.9%)
Platelet  aggregation inhibitors 9105 (17.6%) 985 (16.1%) 518 (13.6%) 997 (14.9%) 6082 (18.8%) 523 (19.7%)
Diuretics  19,051 (36.9%) 2131 (34.7%) 1211 (31.8%) 2223 (33.2%) 12,281 (37.9%) 1205 (45.5%)
Beta  blocking agents 21,113 (40.8%) 2075 (33.8%) 1576 (41.4%) 2374 (35.5%) 13,867 (42.8%) 1221 (46.1%)
Calcium  channel blockers 10,389 (20.1%) 1197 (19.5%) 735 (19.3%) 1266 (18.9%) 6669 (20.6%) 522 (19.7%)
Agents  acting on the renin--angiotensin system 28,880 (55.9%) 3469 (56.5%) 2070 (54.4%) 3575 (53.4%) 18,377 (56.7%) 1389 (52.4%)
Statins  21,922 (42.4%) 2657 (43.3%) 1522 (40.0%) 2722 (40.7%) 13,714 (42.3%) 1307 (49.3%)
Non-steroidal anti-inflammatory drugs 6429 (12.4%) 1805 (29.4%) 623 (16.4%) 1594 (23.8%) 2239 (6.9%) 168 (6.3%)
SD: standard deviation, GFR: glomerular filtration rate, BMI: body mass index.
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Table  2  Descriptive  of  adherence  and  discontinuation  rates  of  anticoagulants  in  naive  and  non-naive  patients.
First  year  discontinuation,  n  (%)
Naive  patients  Total  (n  =  21,657)  Apixaban  (n  =  958)  Dabigatran  (n  =  1152)  Rivaroxaban  (n  =  1315)  Acenocumarol  (n  =  16,953)  Warfarin  (n  =  1279)
No  discontinuation  11,502  (53.1%)  375  (39.1%)  425  (36.9%)  499  (37.9%)  9634  (56.8%)  569  (44.5%)
Discontinuation at  1st  month  1854  (8.6%)  317  (33.1%)  279  (24.2%)  402  (30.6%)  840  (5.0%)  16  (1.3%)
Discontinuations at  6th  month  6420  (29.6%)  472  (49.3%)  564  (49.0%)  679  (51.6%)  3648  (21.5%)  457  (35.7%)
Discontinuations at  1st  year  10,155  (46.9%)  583  (60.9%)  727  (63.1%)  816  (62.1%)  6719  (39.6%)  710  (55.5%)
Non-naive patients  Total  (n  =  418)  Apixaban  (n  =  124)  Dabigatran  (n  =  103)  Rivaroxaban  (n  =  144)  Acenocumarol  (n  =  12)  Warfarin  (n  =  35)
No  discontinuation  258  (61.7%)  82  (66.1%)  50  (48.5%)  93  (64.6%)  6  (50.0%)  27  (77.1%)
Discontinuation at  1st  month  23  (5.5%)  2  (1.6%)  13  (12.6%)  7  (4.9%)  1  (8.3%)  0  (0.0%)
Discontinuations at  6th  month  99  (23.7%)  19  (15.3%)  39  (37.9%)  33  (22.9%)  5  (41.7%)  3  (8.6%)
Discontinuations at  1st  year  160  (38.3%)  42  (33.9%)  53  (51.5%)  51  (35.4%)  6  (50.0%)  8  (22.9%)
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Table  3  Descriptive  statistics  of  adherence  rates  of  direct  oral  anticoagulants  in  naive  and  non-naive  patients.
Medication  possession  ratio,  n  (%)
Naive  patients  (n  =  3425)  Apixaban  (n  =  958)  Dabigatran  (n  =  1152)  Rivaroxaban  (n  =  1315)
Less  than  one  year  of  follow-up  583  (60.9%)  727  (63.1%)  816  (62.1%)
N with  at  least  1  year  of  follow-up  375  (39.1%)  425  (36.9%)  499  (37.9%)
Non-adherence  (<80%) 145  (38.7%)  222  (52.2%)  139  (27.9%)
Good adherence  (≥80%) 230  (61.3%) 203  (47.8%) 360  (80.1%)
MPR, median  (IQR) 90.4  (53.4--98.6) 79.5  (72.3--95.3) 92.6  (77.1--99.7)
Non-naive patients  (n  =  371)  Apixaban  (n  =  124)  Dabigatran  (n  =  103)  Rivaroxaban  (n  =  144)
Less  than  one  year  of  follow-up  42  (33.9%)  53  (51.5%)  51  (35.4%)
N with  at  least  1  year  of  follow-up 82  (66.1%)  50  (48.5%)  93  (64.6%)
Non-adherence  (<  80%)  27  (32.9%)  33  (66.0%)  17  (18.3%)
Good adherence  (≥80%)  55  (67.1%)  17  (34.0%)  76  (81.7%)
MPR, median  (IQR)  94.5  (53.4--98.6)  75.1  (71.6--94.7)  99.7  (84.4--99.7)MPR: medication possession ratio, IQR: interquartile range.
criterion  to  anticoagulate  in  NVAF  patients  according  to
guidelines.34,35 Patients  with  highest  risks  of  stroke  were
those  in  the  groups  of  acenocoumarol  and  apixaban,  as
shown  in  previous  studies  for  the  other  VKA,  warfarin.14,22,36
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OAC  treatment  during  at  least  one  year  of  follow-up,  for
KA  the  proportion  was  higher.  Between  them,  rivaroxaban
roup  showed  the  highest  percentage  of  patients  with  good
dherence  at  implementation  (MPR  ≥80)  and  dabigatran  the
owest.  Similar  results  were  also  found  by  Forslund  et  al.22
r  by  Beyer-Westendorf  et  al.23 although  this  last  study  only
nalysed  rivaroxaban  and  dabigatran.  On  the  opposite,  other
tudies  found  higher  MPR  in  apixaban-treated  patients.14,37
Regarding  persistence  to  DOAC  in  naive  patients,  apix-
ban  showed  higher  discontinuation  rates  during  the  first
onth  of  treatment  but  at  one  year,  all  DOAC  showed  sim-
lar  rates.  Several  studies  analysed  discontinuation  rates  at
ifferent  times  during  follow-up.  After  one  year,  apixaban
sers  were  more  persistent  than  other  DOAC  and  VKA  users
n  the  studies  conducted  by  Forslund  et  al.22 and  Johnson
t  al.21
Other  studies  which  analysed  persistence  in  naive
atients  only  included  dabigatran  and  rivaroxaban.  Rivarox-
ban  presented  better  persistence  than  dabigatran  and
KA.23,38
Manzoor  et  al.37 or  Martínez  et  al.39 studied  all  DOAC
ogether  as  a  group.  The  first  one  showed  higher  levels  of
ersistence  to  DOAC  in  anticoagulant-experienced  patients
ver  time.  Martínez  et  al.  found  higher  levels  of  persistence
n  DOAC  versus  VKA  users,  which  slightly  decreased  during
he  first  year  of  follow-up  (from  94.7%  of  persistents  to  DOAC
t  3  months  to  72.9%  at  12  months).
For  anticoagulant-experienced  patients  with  more  than
ne  year  of  follow-up  in  our  study,  again  rivaroxaban  showed
he  largest  proportion  of  patients  with  good  adherence  dur-
ng  implementation.  Only  Manzoor  et  al.37 analysed  MPR
n  non-naive  patients  and  apixaban  showed  higher  MPR  in
pixaban  at  6  months  and  dabigatran  at  9  months.  Dis-
ontinuation  rates  in  our  non-naive  patients  were  much
ower  than  for  the  naive  ones;  during  the  first  month  since
reatment  initiation  1.6%  apixaban,  4.9%  rivaroxaban  and
2.6%  dabigatran  patients  discontinued  the  treatment,  and
fter  one  year  rivaroxaban  users  showed  lower  persistence
ates  (48.5%)  than  apixaban  and  dabigatran  (66.1%  and
4.6%,  respectively).  Manzoor  et  al.37 compared  persistence
etween  naive  and  non-naive  patients  receiving  DOAC  and
he  last  ones  showed  higher  levels  of  persistence.  Johnson
t  al.21 described  similar  discontinuation  rates  than  for  naive
atients  and  at  the  end-of  follow-up  patients  prescribed
pixaban  showed  improved  persistence  over  dabigatran,
ivaroxaban  and  VKA.
The  differences  in  treatment  persistence  between  naive
nd  anticoagulant-experienced  patients  in  our  study  could
e  motivated  by  a  better  knowledge  of  the  anticoagulation
mportance  of  these  patients  who  previously  received  mainly
KA,  and  they  were  used  to  attend  monthly  to  PHC  cen-
res  for  INR  determination  and  had  optimal  levels  of  drug
dherence.
Suboptimal  adherence  to  anticoagulant  therapy  places
atients  with  AF  at  risk  for  stroke  or  bleeding  complications.
ur  study  concludes  as  most  observational  studies,  that  the
uidelines  recommendations  regarding  anticoagulant  ther-
py  are  not  routinely  followed  in  clinical  practice,  and
dherence  is  substantially  lower  than  in  clinical  trials.3,40
Some  specific  limitations  in  our  database  are  the  lack
f  association  between  GP’s  prescriptions  and  dispensing
ssociated  with  these  prescriptions.  This  study  has  missingM.  Giner-Soriano  et  al.
ata  from  pharmacy  claims  and  for  some  variables  as  it  is
ommon  in  observational  studies  using  electronic  databases
information  bias).  The  strengths  of  our  study  are  repre-
entativeness  for  the  general  population,  with  a  database
hat  covers  almost  the  80%  of  the  Catalonian  population,
ith  complete  sociodemographic  and  health  records,  long
ollow-up,  and  real  clinical  practice  data.
What is known on the topic
•  The  level  of  utilisation  of  the  different  DOAC  in
stroke  prevention  in  NVAF  has  shown  to  be  differ-
ent  among  countries,  and  several  cohort  studies  have
shown  dissimilar  results  on  adherence,  effectiveness
and  safety  of  these  drugs.
•  Adequate  levels  of  adherence  and  persistence  to
anticoagulant  treatment  have  shown  to  decrease  the
occurrence  of  embolic  events.
What  this  study  contributes
•  Vitamin  K  antagonists  are  still  the  first  option  to  anti-
coagulate  NVAF  patients  in  our  setting.
•  We  measured  adherence  and  persistence  for  DOAC
patients.  Adherence  was  higher  for  rivaroxaban,  fol-
lowed  by  apixaban  and  dabigatran.
•  Persistence  to  DOAC  was  low  in  our  setting,  which
may  result  in  higher  risk  of  thromboembolic  events.
Discontinuation  rates  were  higher  in  naive  than  in
non-naive  patients.  This  may  be  caused  by  better
knowledge  of  the  importance  of  treatment  adher-
ence  in  patients  who  have  previously  received  VKA,
which  need  a  more  strict  management.
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